Developer of anticancer drugs designed to treat cancer patients. The company's drugs have biomarkers that predict therapeutic response, enabling healthcare providers to cure their patients and improve their lives.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Secondary Transaction - Private | 000.00 | Completed | Profitable | |||
5. Later Stage VC (Series C) | 01-Aug-2021 | 000.00 | 000.00 | Completed | Profitable | |
4. Early Stage VC (Series B) | 08-Jul-2019 | 00.000 | 0000 | Completed | Profitable | |
3. Early Stage VC (Series A) | 08-Oct-2018 | 000.00 | 000.00 | Completed | Pre-Clinical Trials | |
2. Seed Round | 01-Apr-2018 | $4.34M | $4.34M | Completed | Pre-Clinical Trials | |
1. Corporate | 27-Dec-2016 | $2.11K | $2.11K | 00.000 | Completed | Startup |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3819300-A4 | Biomarker-based therapeutic composition | Pending | 06-Sep-2019 | 0000000000 | 0 |
EP-3819300-A1 | Biomarker-based therapeutic composition | Pending | 06-Sep-2019 | 0000000000 | |
JP-6955630-B2 | Thienopyridine derivative and pharmaceutical composition containing it | Active | 08-Mar-2018 | 000000000 | |
JP-2021500378-A | Thienopyridine derivative and pharmaceutical composition containing it | Granted | 08-Mar-2018 | 0000000000 | |
US-20210317133-A1 | Thienopyridine derivatives and pharmaceutical composition comprising same | Pending | 08-Mar-2018 | A61P35/00 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Jin Dong-Hoon | Co-Founder & Co-Chief Executive Officer |
Growth Rate
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Ebest Investment & Securities | Investment Bank | Minority | 000 0000 | 000000 0 | |
Elohim Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
G2G Private Equity | Venture Capital | Minority | 000 0000 | 000000 0 | |
Lead Compass Investment | Venture Capital | Minority | 000 0000 | 000000 0 | |
Seoul Investment Partners | Venture Capital | Minority | 000 0000 | 000000 0 |